Oral healthcare for HIV-infected patients: An international perspective

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 3, 2008, Pages 387-404

  Hegarty, Anne M ^a   Chaudhry, S I ^a   Hodgson, T A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS; Candidosis; HIV; Kaposi's sarcoma; Lymphoma; Oral; Ulceration

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTACID AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CIDOFOVIR; CIMETIDINE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN; DIAZEPAM; DIDANOSINE; FLUCONAZOLE; FLUORIDE; HEMOPOIETIC GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LEVAMISOLE; MICONAZOLE; NYSTATIN; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; UNINDEXED DRUG; WARFARIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; CANCER SURGERY; CANDIDA ALBICANS; CARBON DIOXIDE LASER; CD4 LYMPHOCYTE COUNT; CHEILITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CRYOTHERAPY; DENTAL CARIES; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DYSGEUSIA; ERYTHEMA MULTIFORME; EUROPE; FOLLOW UP; FUNGUS ISOLATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; INFECTION RISK; KAPOSI SARCOMA; LEUKOPLAKIA; MOUTH CANCER; MOUTH DISEASE; MOUTH HYGIENE; MOUTH ULCER; NONHODGKIN LYMPHOMA; NONHUMAN; NORTH AMERICA; OPPORTUNISTIC INFECTION; ORAL SURGERY; PARESTHESIA; PERIODONTAL DISEASE; PREVALENCE; PUBLIC HEALTH SERVICE; RECURRENT DISEASE; REVIEW; SALIVARY GLAND DISEASE; SOCIOECONOMICS; THRUSH; VERRUCA VULGARIS; WART VIRUS; XEROSTOMIA; AIDS RELATED COMPLEX; HERPES VIRUS INFECTION; INTERNATIONAL COOPERATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DENTAL CARIES; HERPESVIRIDAE INFECTIONS; HIV INFECTIONS; HUMANS; INTERNATIONALITY; MOUTH DISEASES; ORAL HYGIENE; RECURRENCE;

EID: 39049094779     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.3.387     Document Type: Review

References (142)

1. Agbelusi GA. Wright AA. Oral lesions as indicators of HIV infection among routine dental patients in Lagos, Nigeria. Oral Dis 2005;11(6):370-3
2. Hodgson TA, Naidoo S, Chidzonga M, et al. (A1) Identification of oral health care needs in children and adults, management of oral diseases. Adv Dent Res 2006;19(1):106-17
3. Lorenz KA, Shapiro MF, Asch SM, et al. Associations of symptoms and health-related quality of life: findings from a national study of persons with HIV infection. Ann Intern Med 2001; 134(9 Pt 2):854-60
4. Coulter ID, Heslin KC, Marcus M, et al. Associations of self-reported oral health with physical and mental health in a nationally representative sample of HIV persons receiving medical care. Qual Life Res 2002;11(1):57-70
5. EC-Clearinghouse and WHO Classification and diagnostic criteria for oral lesions in HIV infection. EC-Clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus. J Oral Pathol Med 1993;22(7):289-91
6. Gillespie GM, Marino R. Oral manifestations of HIV infection: a Panamerican perspective. J Oral Pathol Med 1993;22(1):2-7
7. Robinson PG. The significance and management of periodontal lesions in HIV infection. Oral Dis 2002;8(Suppl 2):91-7
8. Hodgson TA. Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res 2006;19(1):57-62
9. Patton LL, Mckaig R, Strauss R, et al. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89(3):299-304
10. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 2000;29(7):336-41
11. Greenspan D, Canchola AJ, Macphail LA, et al. Effect of highly active antiretroviral therapy on frequency of oral warts. lancet 2001;357(9266):1411-2
12. Bretz WA, Flaitz C, Moretti A, et al. Medication usage and dental caries outcome-related variables in HIV/AIDS patients. AIDS Patient. Care STDS 2000;14(10):549-54
13. Phelan JA, Mulligan R, Nelson E, et al. Dental caries in HIV-seropositive women. J Dent Res 2004;83(11):869-73
14. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 2005;83(9):700-6
15. Ranganathan K, Umadevi M, Saraswathi TR, et al. Oral lesions and conditions associated with human immunodeficiency virus infection in 1000 South Indian patients. Ann Acad Med Singapore 2004;33(4 Suppl):37-42
16. Umadevi KM, Ranganatban K, Pavithra S, et al. Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India. J Oral Pathol Med 2007;36(3):136-41
17. Ramos-Gomez FJ, Flaitz C, Catapano P, et al. Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection. J Clin Pediatr Dent 1999;23(2):85-96
18. Okunseri C, Badner V, Wiznia, A. Rosenberg M. Prevalence of oral lesions and percent CD4+ T-lymphocytes in HIV-infected children on antiretroviral therapy. AIDS Patient Care STDS 2003;17(1):5-11
19. Pongsiriwet S, Iamaroon A. Kanjanavanit S, et al. Oral lesions and dental caries status in perinatally HIV-infected children in Northern Thailand. Int J Paediatr Dent 2003;13(3):180-5
20. Naidoo S, Chikte U. Oro-facial manifestations in paediatric HIV: a comparative study of institutionalized and hospital outpatients. Oral Dis 2004;10(1):13-8
21. Ranganathan K, Hemalatha R. Oral lesions in HIV infection in developing countries: an overview. Adv Dent Res 2006;19(1):63-8
22. Miziara ID, Filho BC, Weber R. Oral lesions in Brazilian HIV-infected children undergoing HAART. Int J Pediatr Otorhinolaryngol 2006;70(6):1089-96
23. Soares LF, De Araujo Castro GF, De Souza IP, Pinheiro M. Pediatric HIV-related oral manifestations: a five-year retrospective study. Pesqui Odontol Bras 2004;18(1):6-11
24. Ranganathan K, Reddy BV, Kumarasamy N, et al. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south Indian patients. Oral Dis 2000;6(3):152-7
25. Ship JA. Vissink A, Challacombe SJ. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl):S6-14
26. Anteyi KO, Thacher TD, Yohanna S, Idoko JI. Oral manifestations of HIV-AIDS in Nigerian patients. Int J STD AIDS 2003;14(6):395-8
27. Kerdpon D, Pongsiriwet S, Pangsomboon K, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Dis 2004;10(3):138-44
28. Chattopadhyay A, Caplan DJ, Slade GD, et al. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dent Oral Epidemiol 2005;33(1):35-44
29. Greenspan D, Gange SJ, Phelan JA, et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res 2004;83(2):145-50
30. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92(6):623-8
31. Ramirez-Amador V, Ponce-De-Leon S, Sierra-Madero J, et al. Synchronous kinetics of CD4+ lymphocytes and viral load before the onset of oral candidosis and hairy leukoplakia in a cohort of Mexican HIV-infected patients. AIDS Res Hum Retroviruses 2005;21(12):981-90
32. Baccaglini L, Atkinson JC, Patton LL. et al. Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl):S50-23
33. Albougy HA, Naidoo S. A systematic review of the management of oral candidiasis associated with HIV/AIDS. J South African Dental Assoc 2002;57(11):457-66
34. Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92(2):170-9
35. Pankhurst C. Candidiasis (oropharyngeal). Clin Evid 2005;(13):1701-16
36. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2006;3:CD003940
37. Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004;53(RR-14):1-92
38. Blignaut E, Patton LL, Nittayananta W, et al. (A3) HIV Phenotypes, oral lesions, and management of HIV-related disease. Adv Dent Res 2006; 19(1):122-9
39. Nittayananta W, Chanowanna N, Sripatanakul S, Winn T. Risk factors associated with oral lesions in HIV-infected heterosexual people and intravenous drug users in Thailand. J Oral Pathol med 2001;30(4):224-30
40. Redding SW, Farinacci GC, Smith JA et al. Comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection. Spec Care Dentist 1992;12(1):24-7
41. Van Roey J, Haxaire M, Kamya M, et al. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2004;35(2):144-50
42. Barasch A, Safford MM, Pkute-Marcus I, Fine DH. Efficacy of chlorhexidine gluconate rinse for treatment and prevention of oral candidiasis in HIV-infected children: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97(2):204-7
43. Patel M, Shackleton JT, Coogan MM. Effect of antifungal treatment on the Prevalence of yeasts in HIV-infected subjects. J Med Microbiol 2006;55(Pt 9):1279-84
44. Vazquez JA, Zawawi AA. Efficacy of alcohol-based and alcohol-free melaleuca oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS. HIV Clin Trials 2002;3(5):379-85
45. Abirami CP, Venugopal PV. Antifungal activity of three mouth rinses - in vitro study. Indian J Pathol Microbiol 2005;48(1):434
46. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005;41(10):1473-80
47. Hahn AM, Huye LE, Ning S. et al. Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J Virol 2005,79(15):10040-52
48. Komatsu TL, Rivero ER, Gallottini De Magalhaes MH, Nunes PD. Epstein-Barr virus in oral hairy leukoplakia scrapes: identification by PCR. Pesqui Odontol Bras 2005;19(4):317-21
49. Dias EP, Israel MS, Silva Junior A. et al. Prevalence of oral hairy leukoplakia in 120 pediatric patients infected with HIV-1. Braz Oral Res 2006;20(2):103-7
50. Ramos-Gomez F. Dental considerations for the paediatric AIDS/HIV patient. Oral Dis 2002;8(Suppl 2):49-54
51. Patton LL, Mckaig RG, Strauss RP Eton JJ Jr. Oral manifestations of HIV in a southeast USA population. Oral Dis 1998;4(3):164-9
52. Shiboski CH, Hilton JF, Neuhaus JM, et al. Human immunodeficiency virus-related oral manifestations and gender. A longitudinal analysis. The University of California, San Francisco Oral AIDS Center Epidemiology Collaborative Group. Arch Intern Med 1996;156(19):2249-54
53. Sharma G, Pai KM, Suhas S, et al. Oral manifestations in HIV/AIDS infected patients from India. Oral Dis 2006;12(6):537-42
54. Moura MD, Grossmann SM, Fonseca LM, et al. Risk factors for oral hairy leukoplakia in HIV-infected adults of Brazil. J Oral Pathol Med 2006;35(6):321-6
55. Logan RM, Coates EA, Pierce AM, Wilson DF. A retrospective analysis of oral hairy leukoplakia in South Australia. Aust Dent J 2001;46(2):108-13
56. Miziara ID, Weber R. Oral candidosis and oral hairy leukoplakia as predictors of HAART failure in Brazilian HIV-infected patients. Oral Dis 2006;12(4):402-7
57. Ramirez-Amador V. Esquivel-Pedraza L, Sierra-Madero J, et al. The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients. a 12-year study in a referral center in Mexico. Medicine (Baltimore) 2003;82(1):39-50
58. Hamza OJ, Matee MI, Simon EN, et al. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 2006;6:12
59. Lozada-Nur F. Podophyllin resin 25% for treatment of oral hairy leuakoplakia: an old treatment for a new lesion. J Acquir Immune Defic Syndr 1991;4(5):543-6
60. Lozada-Nur F, Costa C. Retrospective findings of the clinical benefits of podophyllum resin 25% sol on hairy leukoplakia. Clinical results in nine patients. Oral Surg Oral Med Oral Pathol 1992;73(5):555-8
61. Sanchez M, Spielman T, Epstein W, Moy J. Treatment of oral hairy leukoplakia with podophyllin. Arch Dermatol 1992;128(12):1659-
62. Gowdey G, Lee RK, Carpenter WM. Treatment of HIV-related hairy leukoplakia with podophyllum resin 25% solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79(1):64-7
63. Moura MD, Guimaraes TR, Fonseca LM, et al. A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(1):64-71
64. Greenspan D, De Souza YG, Conant MA, et al. Efficacy of desciclovir in the treatment of Epstein-Barr virus infection in oral hairy leukoplakia. J Acquir Immune Defic Syndr 1990;3(6):571-8
65. Walling DM, Flaitz CM, Nichols CM. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J Infect Dis 2003;188(6):883-90
66. Resnick L, Herbst JS, Ablashi DV, et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 1988;259(3):384-8
67. Albrecht H, Stellbrink HJ, Brewster D, Greten H. Resolution of oral hairy leukoplakia during treatment with foscarnet. AIDS 1994;8(7):1014-6
68. Herbst JS, Morgan J, Raab-Traub N, Resnick L. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia. J Am Acad Dermatol 1989;21(4 Pt 1):753-6
69. Schofer H, Ochsendorf FR, Helm EB, Milbradt R. Treatment of oral 'hairy' leukoplakia in AIDS patients with viramin A acid (topically) or acyclovir (systemically). Dermatologica 1987;174(3):150-1
70. Reznik DA. Oral manifestations of HIV disease. Top HIV Med 2005;13(5):143-8
71. Lager I, Altini M, Coleman H, Ali H. Oral Kaposi's sarcoma: a clinicopathologic study from South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96(6):701-10
72. Mwanda WO, Whalen C, Remick SC. Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East Afr Med J 2005;82(9 Suppl):S133-4
73. Casper C. Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. Herpes 2006;13(2):42-7
74. Ramirez-Amador V, Naya-Saavedra G, Calva JJ, et al. HIV-related oral lesions, demographic factors, clinical staging and anti-retroviral use. Arch Med Res 2006;37(5):646-54
75. Di LG, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 2007;8(2):167-76
76. Stebbing J, Portsmouth S, Gotch F, Gazzard B. Kaposi's sarcoma - an update. Int J STD AIDS 2003;14(4):225-7
77. Epstein JB, Lozada-Nur F. Mcleod WA, Spinelli J. Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine. Cancer 1989;64(12):2424-30
78. Ramirez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol 2002;38(5):460-7
79. Sulis E, Floris C, Sulis ML, et al. Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma. Eur J Cancer Clin Oncol 1989;25(4):759-61
80. Ioannidis JP, Collier AC, Cooper, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998;178(2):349-59
81. Tappero M Berger TG, Kaplan LD, et al. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a Phase II trial. J Acquir Immune Defic Syndr 1991,4(9):839-46
82. Cattelan AM, Trevenzoli M, Aversa SM. Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs 2004;13(5):501-13
83. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95(1):147-54
84. Autier J, Picard-Dahan C, Marinho E, et al. Docetaxel in anthracycline-pretreated AIDS-relared Kaposi's sarcoma: a retrospective study. Br J Dermatol 2005;152(5):1026-9
85. Hodgson TA, Kondowe W, Molyneux EM, et al. Thalidomide for palliation of Kaposi's sarcoma in Malawian children. Pediatr Blood Cancer 2005;44:292
86. Basu D,Williams FM, Ahn CW, Reveille JD. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arthritis Rheum 2006;55(3):466-72
87. Nicolatou-Galitis O, Velegraki A, Paikos S, et al. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004;10(3):145-50
88. Craven DE, Duncan RA. Stram JR, et al. Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults. Ann Intern Med 1998;128(6):455-9
89. Owotade FJ, Fatusi OA. Adebiyi KE, et al. Clinical experience with parotid gland enlargement in HIV infection: a report of five cases in Nigeria. J Contemp Dent Pract 2005;6(1):136-45
90. Katz SL, Davison WC. HIV-infected pediatric patients. NC Med J 1992;53(10):509
91. Dave SP, Pernas FG, Roy S. The benign lymphoepithelial cyst and a classification system for lymphocytic parotid gland enlargement in the pediatric HIV population. Laryngoscope 2007,117(1):106-13
92. Porter SR, Scully C. Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97(1):28-46
93. King MD, Reznik DA, O'daniels CM, et al. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002;34(5):641-8
94. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sex behavior and HIV serostarus. J Infect Dis 2004;189(4):686-98
95. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004;328(1):57-63
96. Syrjanen S. PL7 Oral viral infections that could be transmitted oro-genitally. Oral Dis 2006;12(Suppl 1):2
97. Regezi JA, Greenspan D, Greenspan JS, et al. HPV-associated epithelial atypia in oral war in HIV+ patients. J Cutan Pathol 1994;21(3):217-23
98. Regezi JA, Dekker NP, Ramos DM, et al. Proliferation and invasion factors in HIV-associated dysplastic and nondysplastic oral warts and in oral squamous cell carcinoma: an immunohistochemical and RT-PCR evaluation. Oral Surg; Oral Med Oral Pathol Oral Radiol Endod 2002;94(6):724-31
99. Lipke MM. An armamentarium of wart treatments. Clin Med Res 2006;4(4):273-93
100. Girao L, Franca I, Macedo H, et al. Treatment of oral condylomata acuminata in a HIV-1 patient with bleomycin. J Eur Acad Dermatol Venereol 2000;14(4):321-2
101. Derossi SS, Laudenbach J. The management of oral human papillomavirus with topical cidofovir: a case report. Cutis 2004;73(3):191-3
102. Husak R, Zouboulis CC, Sander-Bahr C, et al. Refractory human papillomavirus-associated oral warts treated topically with 1-3% cidofovir solutions in human immunodeficiency virus type 1-infected patients. Br J Dermatol 2005;152(3):590-1
103. Lozada-Nur F, Glick M, Schubert M. Silverberg I. Use of intralesional interferon-alpha for the treatment of recalcitrant oral warts in patients with AIDS: a report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92(6):617-22
104. Wargon O. Cimetidine for mucosal warts in an HIV positive adult. Australas J Dermatol 1996;37(3):149-50
105. Diz Dios P, Sopena B, Cameselle J, et al. Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers. Arch Otolaryngol Head Neck Surg 2000; 126(1):89-92
106. Kerr AR, Ship A Management strategies for Hiv-associated aphthous stomatitis. Am J Clin Dermatol 2003;4(10):669-80
107. Glick M, Muzyka BC. Alternative therapies for major aphthous ulcers in AIDS patients. J Am Dent Assoc 1992; 123(7):61-5
108. Ramirez-Amador VA, Esquivel-Pedraza L, Ponre-De-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis 1999;28(4):892-4
109. Guckian M, Dransfield I, Hay P, Dalgleish AG. Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Cin Exp Immunol 2000;121(3):472-9
110. Sherry K. Thalidomide in the management of recurrent aphthous ulcerations in patients who are HIV-positive: a review and case reports. Spec Care Dentist 2005;25(5):236-41
111. Miziari ID, Raujo Filho BC, Weber R. AIDS and Recurrent Aphthous Stomatitis. Rev Bras Otorrinolaringol (Engl Ed) 2005;71(4):517-20
112. Herranz P, Arribas JR, Navarro A, et al, Successful treatment of aphthous ulcerations in AIDS patients using topical granulocyte-macrophage colony stimulating factor. Br J Dermatol 2000;142(1):171-6
113. Epstein JB, Cabay RJ, Glick M. Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100(5):571-8
114. Berretta M, Cinelli R, Martellotta F, et al. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003;22(42):6646-59
115. Lester R, Li C, Phillips P, et al. Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases. Leuk Lymphoma 2004;45(9):1881-5
116. Kao GD, Devine P, Mirza N. Oral cavity and oropharyngeal tumors in human immunodeficiency virus-positive patients: acute response to radiation therapy. Arch Otolaryngol Head Neck Surg 1999;125(8):873-6
117. Zapater E, Bagan JV, Campos A, et al. Non-Hodgkin's lymphoma of the head and neck in association with HIV infection. Ann Otolaryngol Chir Cervicofac 1996;113(2):69-72
118. Fleming P, Palmer NO. Pharmaceutical prescribing for children. Part 6. Dental management and prescribing for the immunocompromised child. Prim Dent Care 2006;13(4):135-9
119. Brown JB, Rosenstein D, Mullooly J, et al. Impact of intensified dental care on outcomes in human immunodeficiency virus infection. AIDS Patient Care STDS 2002;16(10):479-86
120. Eldridge K, Gallagher JE. Dental caries prevalence and dental health behaviour in HIV infected children. Int J Paediatr Dent 2000;10(1):19-26
121. Yeung SC, Stewart GJ, Cooper DA, Sindhusake D. Progression of periodontal disease in HIV seropositive patients. J Periodontol 1993;64(7):651-7
122. Umadevi M, Adeyemi O, Patel M, et al. (B2) Periodontal diseases and other bacterial infections. Adv Dent Res 2006;19(1):139-45
123. Schmidt M. HIV-periodontal disease. A review of research prospects: a South African and Namibian perspective. SADJ 1999;54(12):636-9
124. Hofer D, Hammerle CH, Grassi M, Lang NP. Long-term results of supportive periodontal therapy (SPT) in HIV-seropositive and HIV-seronegative patients. J Clin Periodontol 2002;29(7):630-7
125. Reddy J. Control of HIV/AIDS and AIDS-related conditions in Africa with special reference to periodontal diseases. J Int Acad Periodontol 2007;9(1):2-12
126. Yin MT, Dobkin JF, Grbic JT. Epidemiology, pathogenesis, and management of human immunodeficiency virus infection in patients with periodontal disease. Periodontol 2007;44:55-81
127. Baily GG, Perry FM, Denning DW, Mandal BK Fluconazole-resistant candidosis in an HIV cohort AIDS 1994;8(6):787-92
128. Hammer KA, Carson CF, Riley TV. Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae. J Antimicrob Chemother 2004;53(6):1081-5
129. Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Eur J Cancer B Oral Oncol 1995;31B(4):280-5
130. Ramirez-Amador V, Naya-Saavedra G, Calva JJ, et al. HIV-related oral lesions, demographic factors, clinical staging and anti-retroviral use. Arch Med Res 2006;37(5):646-54
131. Bidault P, Chandad F, Grenier D. Systemic antibiotic therapy in the treatment of periodontitis. J Can Dent Assoc 2007;73(6):515-20
132. Ravera M, Reggiori A, Agliata AM, Rocco RP. Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients. Emerg Infect Dis 1999;5(2):274-7
133. Fichtenbaum CJ, Zackin R, Rajicic N, et al. Amphotericin B oral suspension for fluconazole refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS 2000; 14(7):845-52
134. Muzyka BC, Glick M. Sclerotherapy for the treatment of nodular intraoral Kaposi's sarcoma in patients with AIDS. N EngI J Med 1993;328(3):210-11
135. Lucatorto FM, Sapp JR Treatment of oral Kaposi's sarcoma with a sclerosing agent in AIDS patients. A preliminary study. Oral Surg Oral Med Oral Pathol 1993;75(2):192-8
136. Mccormick SU. Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up. J Oral Maxillofac Surg 1996;54(5):583-7
137. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002;8(Suppl 2):34-9
138. Navazesh M, Mulligan R, Barron Y, et al. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95(6):693-8
139. Miller CS, Triplett RG. Minimizing risk of infection using a carbon dioxide laser. Spec Care Dentist 1991; 11(4):155-7
140. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336(21):1487-93
141. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. J Infect Dis 2001;183(2):343-6
142. CEBM.net. Oxford Centre for Evidence-based Medicine (UK). Available from: URL: www.cebm.net/index.asp [last accessed 20 December, 2007]